The myth: AI is transforming medical devices.

Right now. On scale. Consequently, the conference keynotes say so. The investor decks confirm it. As a result - if you are not already deploying AI, you are falling behind. The data tells a different story.

Still Mostly in the Pilot Phase

The global market for AI-enabled medical devices is projected at $18.9 billion in 2025, and approval numbers are climbing. However, within companies, the picture is far less impressive. A 2024 survey of MedTech executives found that although roughly two-thirds say their companies are implementing generative AI, about half remain in the pilot phase and fewer than 20 per cent are genuinely scaling with successful results. First thing to remember: Pilots are not products. And in a regulated industry, the distance between the two is substantial.

The Regulatory Barrier Nobody Wants to Talk About

AI adoption in MedTech has been forced into a plodding pattern in the face of regulatory compliance. This with concerns around risk classification, transparency, data quality, potential bias, and integration into existing workflows challenging regulatory bodies, before even considering AI adaptability and the need for re-authorization. Unquestionably, in the EU, the situation has become more complex. AI systems embedded in medical devices that qualify as high-risk under the AI Act must now comply with requirements that go above and beyond those already demanded by MDR and IVDR. Manufacturers are not navigating one framework; in fact they are navigating two, simultaneously, with limited harmonized guidance and shrinking notified body capacity.

MedTech Europe has been direct: without clearer rules, manufacturers risk being caught between overlapping legal requirements, unclear definitions, and regulatory bottlenecks that delay patient access to technologies that are, in principle, already safe and effective.

The Strategy Gap Is the Real Problem

Technology readiness is not a constraint. Strategic readiness is. Among MedTech companies already deploying AI, a significant share admit they do not know how to prioritise use cases — and MedTech leaders are notably more likely than their pharma counterparts to lack an effective AI implementation strategy altogether.

Meanwhile, the majority of organisations using predictive AI models have not tested them on their own patient data, and fewer still have evaluated those models for bias. These are not edge cases. They are the norm.

Where AIMEDIQ Fits

This is precisely the gap AIMEDIQ was built to address. Regulatory intelligence on AI in MedTech covering the EU AI Act, MDR/IVDR intersections, FDA guidance on AI/ML-enabled devices, and more is available within a closed, source-referenced system. No generic AI hallucinations. No trawling through guidance documents manually. Just traceable, audit-ready answers when your team needs them. If your organization is serious about AI integration, the regulatory homework comes first. AIMEDIQ helps you do it properly. Read more here